RxDoctor Payments Data

Gemlyn George, MD

Hematology & Oncology · Aurora, CONPI 1336496785

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,890 of the $7,572 with a category attached, or 64.6%. 12 manufacturers reported payments, led by Sanofi at 44.6% of the total. 2025 is the largest year on record at $3,285, more than ten times the $97 reported in 2019.

$7,572in general payments, 2019–2025

Across 30 payments — averaging $252.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • Agios Pharmaceuticals, Inc.$2K
  • AstraZeneca$852
  • Novartis$292
  • Novo Nordisk$125
  • Seagen Inc.$117
  • plus $471 from 6 others
$437,159in research payments, 2019–2025

Across 32 payments — averaging $13,661 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$357K
  • Agios Pharmaceuticals, Inc.$43K
  • Janssen Research & Development, LLC$27K
  • Sanofi$7K
  • Cerus Corporation$3K
  • Argenx US, Inc.$159

What the payments were for

  • Consulting fees$4,89065%
  • Food & beverage$2,46233%
  • Education$2203%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,572 in reported general payments places this provider in the 65th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$28,594
Medicare patients
132
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor14$205,725
XareltoRivaroxaban31$48,807
EliquisApixaban26$34,277
Deferasirox20$18,391
OxycontinOxycodone Hcl23$10,349
Enoxaparin Sodium12$3,682
Oxycodone Hcl106$3,450
Morphine Sulfate ErMorphine Sulfate24$2,959
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$2,317
Hydroxyurea40$1,602
Methadone Hcl48$1,535
Hydromorphone Hcl36$374
Warfarin Sodium17$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Global Blood Therapeutics, Inc.Oxbryta$113$205,72514 claims
Johnson & JohnsonXarelto$99$48,80731 claims
PfizerEliquis$66$34,27726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →